Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of SY-007 in Healthy Subjects
NCT04111523Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Mar 2019
- Primary completion
- May 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SY-007 in ischemic stroke (6 cohorts), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoint: Incidence of adverse events of SY-007 at 7 days. Started Mar 2019; status: completed.
02
Drugs
SY-007
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04111523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111523.